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Objective: Outcomes of open (OR) and endovascular revascularization (ER) for chronic mesenteric ischemia (CMI) were
analyzed with respect to clinical risk stratification.
Methods: The data of 229 consecutive patients treated for CMI with OR (146 patients/265 vessels) or ER (83
patients/105 vessels) between 1991 and 2005 were reviewed. Patients were classified as low-risk or high-risk using
standard scoring systems. End points were mortality and morbidity, recurrence-free survival, and patency rates. A subset
analysis compared 111 patients (208 vessels) who had OR with 58 patients (76 vessels) who had stenting.
Results: The ER patients were significantly older (71  15 vs 65  11 years; P < .05), had higher risk (58% vs 31%), and
fewer vessels revascularized (1.3 0.5 vs 1.8 0.4). Four (2.7%) procedurally related deaths occurred in the OR and two
(2.4%) in the ER group (P  NS). Mortality was higher for high-risk patients (OR, 6.7% vs 0.9%; ER, 4.8% vs 0%; P <
.05), but differences were not significant among low-risk or high-risk OR vs ER patients. OR patients had more
complications (36% vs 18%; P < .001) and longer hospitalization (12  8 vs 3  5 days; P < .001). At 5 years, OR had
improved (P < .05) recurrence-free survival (89%  4% vs 51%  9%), and primary (88%  3% vs 41%  9%) and
secondary patency rates (97% 2% vs 88% 4%). More restenoses (hazard ratio [HR], 5.1; 95% confidence interval [CI],
2.4-10.2), recurrences (HR, 6.7; 95% CI, 3.3-13.8), and reinterventions occurred in the ER group (HR, 4.3; 95% CI,
1.9-9.7). At last follow-up, significant symptom improvement was noted in 137 OR (96%) and 72 ER patients (92%, P
NS). In the subset analysis of patients having first-time operations vs stenting, OR resulted in improved (P < .05)
recurrence-free survival (91%  3% vs 56%  8% at 5 years) and better primary and secondary patency rates (93%  2%
and 98%  1% vs 52%  8% and 93%  4% at 3 years).
Conclusion: OR has similar mortality but higher morbidity and longer hospitalization than ER in low-risk or high-risk
patients with CMI. Both treatments effectively improved symptoms, but restenosis, recurrent symptoms, and reinter-
ventions were more likely in ER patients. These findings may guide treatment selection and counseling of low-risk and
high-risk CMI patients undergoing OR or ER procedures. ( J Vasc Surg 2009;49:1472-9.)Chronic mesenteric ischemia (CMI) is an uncommon
syndrome caused by occlusive disease of at least two of the
three mesenteric arteries. Treatment goals are relief of pain,
restoration of normal weight, and prevention of bowel
infarction. Open revascularization (OR) has been the time-
honored treatment and provides immediate relief of symp-
toms in most patients.1-10 Sustained symptom improve-
ment is noted in 78% to 100% of patients, and 3-year
patency rates are 76% to 100%.1-10 Potential disadvantages
are the mortality (4% to 15%) and morbidity (20% to 30%)
associated with OR.1-10
Endovascular revascularization (ER) has emerged as an
alternative treatment in the elderly or higher-risk patient,
but its use in low-risk operative candidates is not well
defined.11 Mortality rates range from 0% to 11%, symptom
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1472relief occurs in 52% to 80% of patients, and 3-year patency
rates are 40% to 88%.11-24 Direct comparison between OR
and ER is difficult because of inherent differences in patient
characteristics. Choice of therapy is often based on per-
ceived clinical risk and surgeon preference.
The purpose of this study was to analyze the risk-
stratified outcomes in patients treated for CMI with OR or
ER. As a secondary aim, the outcomes of OR and stenting
were compared after excluding patients with prior mesen-
teric interventions, concomitant aortic reconstructions, or
angioplasty alone.
METHODS
The study was approved by the Institutional Review
Board of the Mayo Clinic. We identified all consecutive
patients treated for CMI between June 1, 1991, and June
1, 2005. Patients had typical symptoms of CMI caused by
occlusive atherosclerotic disease treated with OR or ER.
We excluded patients with acute mesenteric ischemia, non-
atherosclerotic causes, and those who had prophylactic
mesenteric reconstruction.
Demographics, clinical characteristics, radiologic and
operative data were obtained from the medical records.
Operative risk was assessed using Society for Vascular Sur-
gery (SVS) scores. Patients were classified into a low-risk or
high-risk category by the presence of at least one high-risk
criterion defined in Table I (online only). Several of these
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mortality after open aortic reconstructions.9,25 Early and
late morbidity and mortality were recorded.
Patency was evaluated using duplex ultrasound (DUS),
computed tomography (CTA) or magnetic resonance an-
giography (MRA), and biplane mesenteric angiography.
Mesenteric run-off vessels were not systematically analyzed,
but revascularization was indicated in the presence of a
suitable target artery with patent runoff. Technical success
was defined as a residual stenosis 30% by angiography.
Follow-up consisted of clinical examination and DUS every
6 months during the first year and annually thereafter.
Patients with restenoses documented by DUS underwent
CTA or conventional angiography, or both.
Statistical analysis. Data were analyzed using SVS
reporting standards.26 End points were mortality, morbid-
ity, symptom improvement, survival, patency rates, and
freedom from recurrent symptoms and reinterventions.
Survival and patency data were analyzed using Kaplan-
Meier estimates, and differences were determined by the
log-rank test. The multivariate Cox proportional hazard
model was used to identify independent predictors of mor-
tality, restenoses, and symptom recurrence requiring rein-
tervention. The Pearson 2 or Fisher exact test was used for
analysis of categoric variables. Differences between means
were tested with two-sided t test, the Wilcoxon rank sum
test, or theMann-Whitney test. A value of P .05 was used
to determine statistical significance.
RESULTS
Patient population. There were 229 patients (64
men; 165 women) who were mean age of 67  13 years.
Treatment was OR in 146 patients (265 vessels) and ER in
83 (105 vessels). Clinical presentation was similar in both
groups (Table II, online only), except for longer duration
of symptoms in OR patients (9.7 8.1 vs 6.5 8 months;
P  .008).
Clinical risk assessment. The ER group had more
high-risk patients (58% vs 31%; P  .001). Significant
differences (P  .05) in the ER group, summarized in
Table III (online only), included older age, more men,
higher SVS scores, and more coronary, pulmonary, and
renal disease. Clinical variables were similar for low-risk
patients in both groups. High-risk ER patients, however,
were older (80  7 vs 71  11 years) and had more
coronary artery disease (88% vs 69%), heart failure (42% vs
22%), and renal insufficiency (46% vs 22%) compared with
high-risk OR patients (P  .05).
Angiographic features. The extent of mesenteric dis-
ease was similar between groups (Table IV, online only).
Overall, 131 patients (57%) had three-vessel disease, 93
(41%) had two-vessel, and 5 (2%) had isolated superior
mesenteric artery (SMA) disease. OR patients had more
celiac artery (CA) and SMAocclusions (34% vs 10%;P .05).
Operative treatment. OR was preferred for low-risk
patients and in those with occlusions, calcified, or longer
lesions. A total of 265 vessels were treated, including 143
SMA, 113 CA, and 9 inferior mesenteric arteries (IMA).Two-vessel revascularization was performed in 113 patients
(77%), single-vessel in 30 (21%), and three-vessel in three
(2%). Bypass was used in 136 patients (93%) and transaortic
endarterectomy in 10 (7%). In 103 patients (70%), a bifur-
cated polyester graft was used from the supraceliac aorta to
the CA and SMA. In 23 patients (16%), concomitant aortic
reconstruction was needed for the mesenteric bypass. Post-
operative medical therapy consisted of aspirin in 71 patients
(49%) and warfarin in six (4%).
Endovascular treatment. ER was preferentially used
in high-risk patients and was applied more broadly for
patients with short-segment (2-cm) stenosis. Access was
obtained through the femoral artery in 72 patients (87%)
and the brachial artery in 11 (13%). Of the 105 arteries (62
SMA, 38 CA, and 5 IMA) treated, balloon-expandable
stents were used in 76 (72%) and angioplasty alone in 29
(28%) (Table V, online only). One vessel was revascularized
in 62 patients (75%), two vessels in 20 (24%), and three
vessels in 1 (1%). Fewer arteries were reconstructed in the
ER group (1.3  0.5 vs 1.8  0.4 vessels; P  .01).
Technical success was 95% (79 of 83), with four technical
failures due to residual stenosis or dissection in two patients
each. Medical therapy consisted of aspirin in 47 patients
(57%), clopidogrel in 40 (48%), and warfarin in 15 (18%).
Early outcome
Symptom improvement. Symptom improvement oc-
curred in 222 patients (97%), but symptoms were un-
changed in 3 (2 OR and 1 ER) and were worse in 4 (1 OR
and 3 ER). Patients treated with ER spent fewer days in the
intensive care unit (ICU, 0.7 3.5 vs 4.6  4.8 days; P 
.0001) and in the hospital (3  5 vs 12  8 days; P 
.0001).
Procedure-related mortality. There were six (2.6%)
early procedure-related deaths, four (2.7%) in the OR and
two (2.4%) in the ER group (P  NS). The mortality rate
for OR was 0.9% (1 of 101) in low-risk, 6.7% (3 of 45) in
high-risk, and 8.6% (2 of 23) in patients who required
aortic replacement. Causes of death weremyocardial infarc-
tion (MI) in two patients and respiratory failure or multi-
system organ failure (MOF) in one patient each. Two
high-risk patients died after ER, one fromMI and the other
from gastrointestinal bleeding (Table VI). No differences
in mortality rates were documented when we compared
low-risk and high-risk patients between groups.
Effect of high-risk criteria. The 30-daymortality rate
was higher for each of the high-risk criteria compared with
the low-risk group, with the exception of age 80 years,
stress-induced cardiac ischemia, and severe left ventricular
dysfunction (Table VII). For the entire cohort, the 30-day
mortality rate increased from 0.7% in low-risk patients to
3.1% with 1 criterion, 12.5% with 2 or 3, 25% with 4 or 5,
and 50% with6 high-risk criteria. Renal insufficiency and
severe pulmonary dysfunction were independently associ-
ated with increased risk of early death (Table VIII).
Procedure-related morbidity. More complications
occurred after OR (P  .05) than with ER (36% vs 18%),
both in low-risk (37% vs 10%) and high-risk subgroups
MOF,
1, forc
dioxid
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and pulmonary problems (15% vs 1%). The incidence of
renal and gastrointestinal complications was similar in both
groups (Table IX, online only).
Three ORs (2%) thrombosed, including two grafts and
Table VI. Procedurally related deaths in patients treated f
revascularization
Patient Age/sex Risk assessment Operation
OR
1 75F Low risk; Cr 1.2 mg/dL MEA
2 75F High risk; Cr 3.1 mg/dL;
DSE–
MEA
3 80F High risk; Cr 2.7 mg/dL;
15% wt loss; severe
AIOD; occluded SMA
AOFB; aortic-
graft-SMA
bypass
4 80F High risk AOIB
Cr 1.3 mg/dL; DSE–;
FEV1 2000 mL; 26%
wt loss; juxtarenal AAA
Aortic-graft-SM
bypass
ER
1 67F High risk; Cr 2.0 mg/dL;
DSE; FEV1 1000
mL; 39% wt loss
Celiac and SM
stent
2 69F High risk; Cr 4.0 mg/dL;
MI  30 days; FEV1
800 mL; 30% wt loss
SMA PTA
AOFB, Aortofemoral bypass; AOIB, aortoiliac bypass; AOID, aortoiliac o
positive); MEA, Mesenteric endarterectomy; MI, myocardial infarction;
transluminal angioplasty; SMA, superior mesenteric artery; wt, weight; FEV
Table VII. Comparison of mortality rates at 30-days and
according to high-risk criteria defined in Table I (online on
High-risk criteria
30-da
Yes
Age 80 y 2.7
Severe pulmonary dysfunction
FEV1  800 mL or DLCO 50% 17
Resting PCO2  50 mm Hg 20
Resting PO2  60 mm Hg 40
Home oxygen therapy 20
Severe cardiac dysfunction
LVEF  25% 3.5
NYHA III or IV angina pectoris 29
Positive cardiac stress test 4.8%
Myocardial infarction 90 days 20
Severe renal insufficiency (Cr  3.0) 50
Multiple high-risk criteria
None (low risk patient) 0.7
1 criteria 3.1
2 to 3 criteria 12.5
4 to 5 criteria 25
6 criteria 50
Cr,Creatinine;DLCO, diffusing capacity of lung for carbonmonoxide; LVEF
not significant; NYHA, New York Heart Association; PCO2, partial carbon
aComparing presence (yes) or absence (no) of mortality.one SMA endarterectomy. An asymptomatic CA limbthrombosis was treated conservatively in one patient and
another underwent revision of SMA limb occlusion. A third
patient with thrombosis after SMA endarterectomy died of
MOF despite thrombectomy and bowel resection.
Intraprocedural complications developed in eight ER
ronic mesenteric ischemia with open or endovascular
Complications Cause of death POD
SMA thrombosis; renal 
respiratory failure; re-
exploration,
thrombectomy, bowel
resection
MOF 52
Cardiac arrest, MI, acute on
chronic renal failure
Cardiac 24
Clostridium difficile colitis,
aspiration pneumonia,
respiratory failure
Pulmonary 37
Massive MI Cardiac 14
Renal failure, no dialysis Massive gastrointestinal
bleeding (no autopsy)
3
Cardiac arrest, MI Cardiac 1
ve disease; Cr, creatinine; DSE, dobutamine stress test ( negative or 
multisystem organ failure; POD, postoperative day; PTA, percutaneous
ed expiratory volume in 1 second.
rs in 229 patients with chronic mesenteric ischemia
tality, % 5-year mortality, %
Pa Yes No Pa
NS 50 30 .06
.02 57 31 .02
.01 34 20 NS
.001 42 33 NS
.01 43 20 .05
NS 36 26 NS
.03 62 32 .03
NS 34 32 NS
0.01 33 20 NS
.01 50 33 .01
27
31
34
47
69
ntricular ejection fraction; FEV1, forced expiratory volume in 1 second;NS,
e pressure; PO2, partial oxygen pressure.or ch
A
A
cclusi5-yea
ly)
y mor
No
2.6
1.4
2.2
1.8
2.2
1.5
1.8
2.1%
2.2
1.8
, left vepatients (10%), including four dissections and four dis-
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 6 Oderich et al 1475lodged stents. These occurred using femoral access, 0.035-
inch guidewire systems, and hand-mounted stents. Two of
the SMA dissections occurred after multiple catheteriza-
tions through the femoral approach because of acute mes-
enteric angulation. Salvage procedures with additional
stents were successful in five patients, but three required
additional interventions for bowel ischemia. One patient
needed SMA endarterectomy and patch angioplasty, an-
other patient was successfully treated with tissue plasmino-
gen activator and repeat stenting, and a third patient
needed sigmoid resection and SMA bypass. Four patients
(3%) required repair of access site complications (2 femoral
and 2 brachial).
Late outcome
Median follow-up was 36 months (range, 4-179
months) in the OR group and 30 months (range, 4-174
months) in the ER group (P  .05). Late follow-up was
available in 218 patients (98%). Objective patency studies
were done in 118 OR (81%) and 51 ER patients (73%),
with single studies in 31 OR (21%) and 12 ER patients
(13%).
Patient survival. Overall 5-year survival was signifi-
cantly higher after OR than ER (72% 5% vs 55 9%; P
.0001), but was similar between low-risk patients in the OR
(74% 4%) and ER groups (70% 8%; PNS, Fig 1,A).
Table VIII. Multivariate analysis of independent factors
associated with mortality, restenoses, and symptom
recurrence in 229 patients treated for chronic mesenteric
ischemia
Variable OR or HR 95% CI P
Early mortality
Renal insufficiency 7.4 1.6-36 .01
Severe pulmonary dysfunctiona 5.2 1.2-23 .02
Late mortality
Renal insufficiency 2.4 1.2-5.0 .01
Male gender 1.8 1.0-3.4 .04
Severe cardiac dysfunctionb 1.6 1.2-2.0 .001
Severe pulmonary dysfunctiona 1.3 1.1-1.5 .008
Age 1.3 1.4-3.8 .05
Restenosis
Endovascular treatment 3.8 1.8-3.9 .0008
Prior mesenteric intervention 1.5 1.0-2.2 .03
SMA diameter  6 mm 1.4 1.3-3.4 .03
Female gender 1.3 1.2-4.7 .05
Symptom recurrence requiring
reintervention
Endovascular treatment 3.2 1.6-3.4 .0008
Diabetes 2.0 1.0-3.8 .04
Prior mesenteric intervention 1.5 1.1-2.2 .03
Female gender 1.4 1.1-2.9 .02
Age 0.98 0.96-1 .06
CI, Confidence interval; HR, hazard ratio; OR, odds ratio; SMA, superior
mesenteric artery.
aSevere pulmonary dysfunction was defined as the presence of any high-risk
pulmonary criteria defined in Table I (online only).
bSevere cardiac dysfunction was defined as the presence of any high-risk
cardiac criteria defined in Table I (online only).Survival in the high-risk subgroups was significantly betterafter OR (67  5% vs 50  8%; P  .04, Fig 1, B). Of the
high-risk criteria defined in Table I (online only), age 80
years, forced expiratory volume in 1 second (FEV1)  800
mL, home oxygen therapy, New York Heart Association
(NYHA) functional class III and IV, and serum creatinine
level3.0 mg/dL, adversely affected survival on univariate
analysis (Table VII). The multivariate model showed renal
insufficiency, male gender, age, and severe cardiac or pul-
monary dysfunction were independently associated with
late death (Table VIII).
Restenosis, symptom recurrence, and repeat inter-
ventions. Restenoses occurred in 10 patients (12 vessels)
treated with OR and in 31 patients (41 vessels) treated with
ER (hazard ratio [HR], 5.1; 95% confidence interval [CI],
2.4-10.2; P  .0001). Multivariate analysis identified en-
dovascular treatment, prior mesenteric intervention, small
(6-mm) SMA diameter, and female gender as indepen-
dent predictors for restenosis (Table VIII).
Recurrent symptoms occurred in eight OR (6%) and 26
ER (31%) patients (HR, 6.7; 95% CI, 3.3-13.8; P .001).
Freedom from recurrent symptoms at 5 years was higher
(P .001) in OR patients vs the ER patients (89% 4% vs
51%  9%; Fig 2), both for low-risk (94%  4% vs 57% 
Fig 1. Kaplan-Meier estimates of patient survival in (A) low-risk
and (B) high-risk patients with chronic mesenteric ischemia
treated with open (OR, solid line) and endovascular revasculariza-
tion (ER, dashed line).9%) and high-risk patients (89% 4% vs 55% 9%). There
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5 years for patients who had single-vessel vs two-vessel OR
(92%  5% and 89%  4%), in the 3-year rates for single-
vessel vs two-vessel ER (57%  7% and 57%  12%), or in
the 2-year rates for angioplasty alone vs stenting (63% 9%
and 59%  8%). Endovascular treatment, diabetes, prior
mesenteric intervention, and female gender were indepen-
dently associated with symptom recurrence requiring re-
peat intervention (Table VIII).
Repeat interventions were needed in all eight OR and
26 ER patients with symptoms because of restenoses (HR,
4.3; 95% CI, 1.9-9.7; P  .0001). Four OR patients
required emergency operations for acute thrombosis (2
revisions and 2 bypasses), and the other fours were treated
with ER (3 stents and 1 angioplasty for chronic symptoms).
Chronic symptoms in 23 ER patients were treated with
additional angioplasty or stenting (multiple in 6), and three
underwent OR to treat acute mesenteric ischemia. No
deaths occurred with repeat interventions in either group,
and all patients reported symptom resolution. At the last
follow-up, 137 OR (96%) and 72 ER patients (92%) con-
ferred symptom improvement (P  NS).
Patency rates. Cumulative primary and secondary pa-
tency rates at 5 years were higher for OR compared with ER
(88% 2% and 97% 2% vs 41% 9% and 88% 4%; P
.005; Fig 3). Primary and secondary patency rates favored
OR in both low-risk (94%  2% and 98%  2% vs 66% 
11% and 79  9%) and high-risk patients (90%  4% and
96  3% vs 65%  9% and 95  3%), and SMA grafts
compared with SMA angioplasty or stent (91%  9% and
97%  2% vs 50%  9% and 88%  6%) or celiac grafts
compared with celiac angioplasty or stent (93%  3% and
98%  2% vs 60%  3% and 91%  2%). In the ER group,
there were no differences in patency rates for angioplasty vs
stents or for SMA vs celiac stents (Fig 4, B online only).
Comparison of first-time stenting vs open revascu-
larization. Treatment consisted of OR in 111 (208 ves-
sels) and stents in 58 (76 vessels), with 93% of the latter
group treated after 1999. There were more high-risk
Fig 2. Kaplan-Meier estimates of survival free of recurrent symp-
toms in patients treated for chronic mesenteric ischemia with open
(OR, solid line) or endovascular revascularization (ER, dashed
line).patients in the stent group (59% vs 29%). Freedom fromrecurrent symptoms at 5 years was 91%  3% for OR and
56% 8% for stenting (P .001). OR was associated with
significantly higher primary and secondary patency rates at 3
years (93% 2% vs 52% 8% and 98% 1% vs 93 4%; P
.05).
DISCUSSION
The interpretation of treatment guidelines for CMI
based on the available literature is difficult for several rea-
sons. First, results of OR (in healthier patients) and ER (in
sicker patients) are not comparable. Second, some reports
have small patient numbers treated over long time periods,
or patients with acute and chronic presentations with a
variety of etiologies such as arteritis and median arcuate
ligament syndrome. Third, reporting standards are incon-
sistent, with no uniform definition of technical success after
ER and lack of objective patency determination in several
studies. To our knowledge, this study is the first to detail
outcomes of mesenteric interventions by clinical risk strat-
ification.
Open mesenteric revascularization has evolved during
Fig 3. Kaplan-Meier estimates of (A) primary and (B) secondary
patency rates in patients treated for chronic mesenteric ischemia
with open (OR, solid line) or endovascular revascularization (ER,
dashed line).the last two decades and is the standard for comparison of
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from complete retrograde revascularization and a low
threshold for concomitant aortic reconstruction to a pref-
erential use of antegrade reconstructions based on the
supraceliac aorta, reserving aortic reconstruction for the
rare patient who needs it for an inflow source or in whom
aortic pathology necessitates repair.1 We have found the
iliac artery to be good source of inflow in high-risk patients
or those with diseased or calcified aortas.
A “high” mortality rate is often cited as the primary
reason for ER in patients with CMI. Contemporary series
of open mesenteric revascularizations have shown improve-
ments in mortality rates, likely due to technical refinements
and advances in medical, anesthetic, and critical care man-
agement.1,6-7 Our overall mortality rate of 2.7% in the OR
group shows these reconstructions can be performed safely.
Importantly, our best (low-risk) operative candidates, 70%
of whom had supraceliac-based reconstructions, had a low
mortality rate of 0.9%. The overall mortality rates were
similar between the OR and ER groups, and there were no
significant differences in mortality when low-risk and high-
risk patients were analyzed separately for OR vs ER proce-
dures. High-risk patients, as defined by our criteria, obvi-
ously impart a higher operative mortality (6.7%), and the
same is true for those who require concomitant aortic
reconstruction (8.9%).
Differences in mortality and outcomes between OR
and ER may be due to lack of risk stratification. The effect
of high-risk criteria, as defined in this study, provides some
useful clinical guidelines. The 30-day mortality rate signif-
icantly increased in any patient with severe pulmonary
dysfunction, NYHA class III or IV angina pectoris, recent
MI, or severe renal insufficiency. The 5-year mortality rate
was significantly higher in patients with low FEV1, low
diffusing lung capacity, home oxygen, NYHA class III or
IV angina pectoris, or severe renal insufficiency. Further-
more, the more high-risk criteria a given patient had, the
higher the 30-day and 5-year mortality rates. A low-risk
patient, defined as having no high-risk criteria, had an
overall mortality rate of 0.7% at 30 days and 27% at 5 years.
With one high-risk criterion, the mortality rates increased
to 3.1% at 30 days and 31% at 5 years. If four or more
high-risk criteria were present, the mortality rate at 30 days
was at least 25%, and more than two-thirds of patients were
dead 5 years. All but one of the six procedurally related
deaths in occurred in high-risk patients. Among these five,
the number of high-risk criteria ranged from two to four,
and the predicted 30-day mortality rate would have been
12.5% to 25%.
Initial symptom improvement is excellent with either
approach. The main advantage of ER is a lower risk of
complications, most notably cardiac and pulmonary prob-
lems. The incidence of complications is nearly half that of
OR. Similar to other reports comparing the two tech-
niques, endovascular interventions result in shorter ICU
and hospital stays, which may translate into a quicker
patient recovery and less cost during the initial hospitaliza-
tion.16,21OR is clearly durable. In this study, freedom from
recurrent symptoms was 89% at 5 years and primary patency
was 88%. The superior durability of openmesenteric recon-
struction over endovascular therapy has been confirmed in
other series.16,21Moreover, patients treated with ER in this
study were five times more likely to develop restenosis,
seven times more likely to have recurrent symptoms, and
four times more likely to undergo another intervention.
Independent predictors for symptom recurrence included
ER, diabetes, prior mesenteric intervention, and female
gender.
Nonetheless, several centers prefer ER for all patients
with suitable lesions, regardless of their clinical risk. The
enthusiasm for endovascular techniques may be due to a
number of factors, including the limited exposure or train-
ing a vascular surgeon has in performing open mesenteric
reconstructions and the high mortality rates (8% to 15%) of
OR in some reports.1,2,7 Our study certainly refutes the
latter argument. However, angioplasty or stenting carries
lower morbidity, faster recovery time, and excellent initial
symptom improvement, albeit at the expense of more
symptomatic restenoses and repeat interventions. Despite
the need for repeat interventions in almost one-third of the
patients in our study, 92% had symptom relief at last
follow-up. Brown et al21 noted 57% of their patients re-
quired repeat intervention, but 93% reported symptom
improvement during follow-up.21 Therefore, if endovasc-
ular therapy is chosen, patients need to be counseled about
the advantages and disadvantages of the technique, and
close follow-up with arterial imaging becomes paramount.
We notedmore dissections and dislodged stents early in
our experience when the femoral approach was preferen-
tially used, stents were hand mounted, and delivery systems
were introduced over 0.035-inch wires. Sarac et al23 re-
ported higher mortality rates in patients who had mesen-
teric interventions by the femoral approach. It is possible
that the femoral approach leads to more catheter manipu-
lation and risk of complications. We now prefer the brachial
artery access in patients with angulated mesenteric origin,
and with the technologic improvements in the delivery
system, the risk of complications has fallen.
Whereas most agree the SMA should be the primary
target for revascularization, no differences were noted in
freedom from recurrent symptoms for single-vessel vs two-
vessel OR or ER. Our preference for OR is to reconstruct
two vessels, because we previously reported that symptom-
atic recurrence after OR occurred when both limbs of a
bifurcated graft failed or when a single graft to the SMA
became stenotic.9 Stenosis of one limb of a bifurcated graft
has not resulted in recurrent symptoms. In contrast, we
have not adopted the same policy as others toward two-
vessel ER. Silva et al22 reported more symptomatic recur-
rences in patients who had single-vessel (24%) vs two-vessel
(6%) stenting, but the difference was not significant (P 
.09). In our study, the initial advantage in symptom-free
survival at 2 years in patients who had two-vessel interven-
tions (73  10% vs 57%  7%) was lost by 3 years.
Therefore, we stent the SMA first, and selectively treat the
JOURNAL OF VASCULAR SURGERY
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stenosis or dissection after treatment. Our study has
several limitations. Because the data were analyzed ret-
rospectively and the study was nonrandomized, we can-
not comment about the exact circumstances that affected
the choice of therapy. Second, despite our risk-stratified
analysis, some of the clinical differences favored the OR
group. This group had more vessels treated and the
high-risk patients were younger and had less coronary
and renal disease than the high-risk patients in the ER
group. These factors could explain differences in late
survival between groups. Third, endovascular technol-
ogy has evolved rapidly, and some of our results would
not reflect the effect of the small-profile systems on
outcome. Finally, although 81% of the OR group and
73% of the ER group had at least one imaging study,
restenoses rates may be underestimated.
CONCLUSIONS
Experienced surgeons can safely perform OR for
CMI, and mortality rates compare favorably with endo-
vascular treatment, albeit at the expense of more compli-
cations and longer hospitalization. Symptom relief is
excellent with both treatment modalities, but endovas-
cular therapy is associated with higher rates of restenosis
and symptom recurrence. Our approach to these patients
continues to evolve. Anatomically low-risk patients with
long segment occlusions or stenosis, heavily calcified
lesions, or atheromatous debris may be better suited for
OR. ER is preferred for high-risk patients and may be an
alternative to OR in low-risk patients with ideally suited
lesions. Whether the preferential use of ER in the low-
risk patient becomes standard of practice is yet to be
determined, but certainly such individuals should be
counseled about the higher rates of repeat interventions
with mesenteric stenting.
We gratefully acknowledge the assistance of Joseph
Miskulin, BS, Rafael Malgor, MD, and Janet Hofer, RN
with data collection andmanagement, and Carl Clingmann
with preparation of medical illustrations.
AUTHOR CONTRIBUTIONS
Conception and design: GO, TB, TS
Analysis and interpretation: GO, TB, TS, SC
Data collection: GO
Writing the article: GO, TB, TS
Critical revision of the article: GO, TB, TS, HB, SC, PG
Final approval of the article: GO, TB, TS, HB, SC, PG
Statistical analysis: GO, TB, TS, SC
Obtained funding: GO
Overall responsibility: GO
REFERENCES
1. Hollier LH, Bernatz PE, Pairolero PC, Payne WS, Osmundson PJ.
Surgical management of chronic intestinal ischemia: a reappraisal. Sur-
gery 1981;90:940-6.2. Cunningham CG, Reilly LM, Rapp JH, Schneider PA, Stoney RJ.
Chronic visceral ischemia. Three decades of progress. Ann Surg 1991;
214:276-87; discussion 287-8.
3. Johnston KW, Lindsay TF, Walker PM, Kalman PG. Mesenteric arterial
bypass grafts: early and late results and suggested surgical approach for
chronic and acute mesenteric ischemia. Surgery 1995;118:1-7.
4. McMillan WD, McCarthy WJ, Bresticker MR, Pearce WH, Schneider
JR, Golan JF, et al. Mesenteric artery bypass: objective patency deter-
mination. J Vasc Surg 1995;21:729-40; discussion 740-1.
5. Moawad J, McKinsey JF, Wyble CW, Bassiouny HS, Schwartz LB,
Gewertz BL. Current results of surgical therapy for chronic mesenteric
ischemia. Arch Surg 1997;132:613-8; discussion 618-9.
6. Kihara TK, Blebea J, Anderson KM, Friedman D, Atnip RG. Risk
factors and outcomes following revascularization for chronic mesenteric
ischemia. Ann Vasc Surg 1999;13:37-44.
7. Mateo RB, O’Hara PJ, Hertzer NR, Mascha EJ, Beven EG, Krajewski
LP. Elective surgical treatment of symptomatic chronic mesenteric
occlusive disease: early results and late outcomes. J Vasc Surg 1999;29:
821-31; discussion 832.
8. Foley MI, Moneta GL, Abou-Zamzam AM Jr, Edwards JM, Taylor
LM Jr, Yeager RA, et al. Revascularization of the superior mesenteric
artery alone for treatment of intestinal ischemia. J Vasc Surg 2000;
32:37-47.
9. Park WM, Cherry KJ Jr, Chua HK, Clark RC, Jenkins G, Harmsen WS,
et al. Current results of open revascularization for chronic mesenteric
ischemia: a standard for comparison. J Vasc Surg 2002;35:853-9.
10. Cho JS, Carr JA, Jacobsen G, Shepard AD, Nypaver TJ, Reddy DJ.
Long-term outcome after mesenteric artery reconstruction: a 37-year
experience. J Vasc Surg 2002;35:453-60.
11. Golden DA, Ring EJ, McLean GK, Freiman DB. Percutaneous trans-
luminal angioplasty in the treatment of abdominal angina. AJR Am J
Roentgenol 1982;139:247-9.
12. Rose SC, Quigley TM, Raker EJ. Revascularization for chronic mesen-
teric ischemia: comparison of operative arterial bypass grafting and
percutaneous transluminal angioplasty. J Vasc Interv Radiol 1995;6:
339-49.
13. Matsumoto AH, Tegtmeyer CJ, Fitzcharles EK, Selby JB Jr, Tribble
CG, Angle JF, et al. Percutaneous transluminal angioplasty of visceral
arterial stenoses: results and long-term clinical follow up. J Vasc Inter-
vent Radiol 1995;6:165-74.
14. Allen RC, Martin GH, Rees CR, Rivera FJ, Talkington CM, Garrett
WV, et al. Mesenteric angioplasty in the treatment of chronic intestinal
ischemia. J Vasc Surg 1996;24:415-21; discussion 421-3.
15. Busquet J. Intravascular stenting in the superior mesenteric artery for
chronic abdominal angina. J Endovasc Surg 1997;4:380-4.
16. Kasirajan K, O’Hara PJ, Gray BH, Hertzer NR, Clair DG, Greenberg
RK, et al. Chronic mesenteric ischemia: open surgery versus percutane-
ous angioplasty and stenting. J Vasc Surg 2001;33:63-71.
17. Cognet F, Ben SalemD, Dranssart M, Cercueil JP, Weiller M, Tatou E,
et al. Chronic mesenteric ischemia: imaging and percutaneous treat-
ment. Radiographics 2002;22:863-79; discussion 879-80.
18. Aburahma AF, Stone PA, Bates MC, Welch CA. Angioplasty/stenting
of the superior mesenteric artery and celiac trunk: early and late out-
comes. J Endovasc Ther 2003;10:1046-53.
19. Sharafuddin MJ, Olson CH, Sun S, Kresowik TF, Corson JD. Endo-
vascular treatment of celiac and mesenteric artery stenoses: applications
and results. J Vasc Surg 2003;38:692-8.
20. van Wanroij JL, van Petersen AS, Huisman AB, Mensink PB, Gerrits
DG, Kolkman JJ, et al. Endovascular treatment of chronic splanchnic
syndrome. Eur J Vasc Endovasc Surg 2004;28:193-200.
21. Brown DJ, Schermerhorn ML, Powell RJ, Fillinger MF, Rzucidlo EM,
Walsh DB, et al. Mesenteric stenting for chronic mesenteric ischemia. J
Vasc Surg 2005;42:268-74.
22. Silva JA, White CJ, Collins TJ, Jenkins JS, Andry ME, Reilly JP, et al.
Endovascular therapy for chronic mesenteric ischemia. J Am Coll
Cardiol 2006;47:944-50.
23. Sarac TP, Altinel O, Kashyap V, Bena L, Lyden S, et al. Endovascular
treatment of stenotic and occluded visceral arteries for chronic mesen-
teric ischemia. J Vasc Surg 2008;47:485-91.
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 6 Oderich et al 147924. Atkins MD, Kwolek CJ, LaMuraglia GM, Brewster DC, Chung TK,
Cambria RP. Surgical revascularization versus endovascular therapy for
chronic mesenteric ischemia: a comparative experience. J Vasc Surg
2007;45:1162-71.
25. Eagle K, Coley CM, Newell JB, Brewster DC, Darling RC, Strauss W,
et al. Combining clinical and thallium data optimizes preoperative
assessment of cardiac risk before major vascular surgery. Ann Int Med26. Rutherford R, Baker JD, Ernest C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
Submitted Feb 6, 2007; accepted Feb 3, 2009.
Additional material for this article may be found online
1989;110:859-66. at www.jvascsurg.org.
RECOUP THE LOUPES
Despite extremely limited resources, surgeons in developing countries work to provide their patients with the best
possible care. For many of these surgeons, technology such as loupes, which facilitate delicate procedures, is simply
out of reach.
One year ago, Loupes Around The World distributed its first pair of loupes to a plastic surgeon in Phnom Penh,
Cambodia. Before Loupes Around The World, this surgeon commonly repaired cleft lips and palates, and treated
trauma patients with maxillofacial injuries without the benefit of surgical magnification. Since then, this not-for-profit
organization has provided loupes to surgeons from Panama to India and continues to receive requests from surgeons
around the world.
Loupes Around The World is now recycling donated loupes via a program called “Recoup the Loupes.” Surgeons
with unused loupes are asked to send them to the foundation; there, repairs can be made to adjustable loupes, and the
telescopes from fixed loupes can be installed into new lenses and frames. For fixed loupes, optical measurements are
taken to ensure that the loupes will meet the needs of each individual surgeon.
Please send your unused loupes to:
David C. Knight, M.D., F.A.C.S.
Loupes Around The World
c/o Surgical Associates of Waterbury
1211 West Main St.
Waterbury, CT 06708
Loupes Around The World accepts loupes made by any manufacturer. For more information about Loupes Around
The World, as well as information about how to contribute, please visit: www.loupesaroundtheworld.org. Upon
receiving loupes, a letter of acknowledgment will be sent to the donor for tax purposes. Loupes Around the World is
a 501(c)3 tax-exempt organization.
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June 20091479.e1 Oderich et alTable I (online only). Definitions of high-risk criteria
for mesenteric artery intervention
Age 80 years
Severe pulmonary dysfunction
FEV1 800 mL or DLCO 50% of predicted
Resting PCO2 50 mm Hg or PO2 60 mm Hg
Home oxygen therapy
Severe cardiac dysfunction
Left ventricular ejection fraction 25%
NYHA class III or IV angina pectoris
Cardiac stress test positive for myocardial ischemia
Myocardial infarction 90 days
Severe renal insufficiency (baseline Cr 3.0 mg/dL)
Cr, Creatinine; DLCO, diffusing capacity of the lung for carbon monoxide;
FEV1, forced expiratory volume in 1 second; NYHA, New York Heart
Association; PCO2, partial pressure of carbon dioxide; PO2, partial pressure of
oxygen.
Table II (online only). Clinical presentation in 229
patients with chronic mesenteric ischemia treated with
open (OR) or endovascular (ER) mesenteric artery
revascularization
Signs and symptoms
OR (n  146) ER (n  83)
P
Mean  SD or
No. (%)
Mean  SD
or No. (%)
Symptom duration, mon 9.7  8.1 6.5  8 .008
Abdominal pain 137 (94) 82 (99) NS
Weight loss 128 (88) 65 (78) NS
Baseline weight, kg 67.3  15 69.6  12.3 NS
Weight at presentation,
kg 57.7  16 60.3  13.0 NS
Absolute weight loss, kg 9.7  6.8 9.3  7.7 NS
Weight loss, % 14.9  10 13.5  10.7 NS
Postprandial pain 109 (75) 60 (72) NS
Abdominal bruit 70 (48) 30 (37) NS
Food fear 68 (47) 36 (43) NS
Diarrhea 61 (42) 30 (36) NS
Nausea and vomiting 48 (33) 18 (22) NS
Prior mesenteric
intervention 12 (8) 6 (7) NS
Prior small-bowel resection 9 (6) 6 (7) NS
Total parenteral nutrition 3 (2) 3 (4) NS
Gastrointestinal bleeding 1 (1) 2 (2) NS
ER, Endovascular revascularization; NS, not significant; OR, open revascu-
larization; SD, standard deviation.
Table III (online only). Demographics, cardiovascular
risk factors, and perioperative risk assessment in 229
patients with chronic mesenteric ischemia treated with
open or endovascular mesenteric artery revascularization
Demographics
OR (n  146) ER (n  83)
P
Mean  SD or
No. (%)
Mean  SD
or No. (%)
Male gender 34 (23) 30 (36) .03
Age y 65  11 71  15 .001
Age 80 y, No. (%) 9 (6) 30 (36) .0001
Cardiovascular risk
factors
Smoking 118 (81) 55 (66) .01
Hypertension 108 (74) 69 (83) NS
Hyperlipidemia 70 (48) 50 (60) NS
Coronary artery disease 54 (37) 55 (66) .001
Positive cardiac stress
test 25 (17) 17 (20) NS
Myocardial infarction
90 d 2 (1) 8 (10) .006
NYHA class III or IV
angina 0 (0) 7 (8) .001
Heart valve disease 24 (17) 24 (29) .02
Arrhythmia 21 (14) 23 (28) .01
Congestive heart failure 11 (8) 21 (25) .001
Ejection fraction 25% 8 (5) 24 (28) .001
Peripheral arterial
disease 51 (35) 32 (39) NS
Chronic pulmonary
disease 31 (21) 29 (35) .02
FEV1 800 mL 9 (6) 13 (15) .03
PO2 60 or PCO2
50 mm Hg 9 (6) 18 (22) .001
Home oxygen
therapy 0 (0) 5 (6) .002
Renal insufficiency (Cr
1.5 mg/dL) 24 (16) 25 (30) .01
Severe (Cr 3.0 mg/
dL) 5 (3) 5 (6) NS
Dialysis-dependent 1 (1) 1 (1) NS
Diabetes 20 (14) 19 (23) NS
Cerebrovascular
diseasea 18 (12) 36 (43) .0001
Perioperative risk
assessment
Any high-risk criteriab 45 (31) 48 (58) .001
SVS score
Cardiac 0.7  0.9 1.3  1.2 .001
Pulmonary 0.4  0.8 0.6  1.1 .05
Renal 0.2  0.5 0.3  0.6 NS
Sum score 1.3  1.5 2.3  1.4 .001
Cr, Creatine; ER, endovascular revascularization; FEV1, forced expiratory
volume in 1 second; NS, not significant; NYHA, New York Heart Associa-
tion; OR, open revascularization; SD, standard deviation; SVS, Society for
Vascular Surgery; PCO2, partial pressure of carbon dioxide; PO2, partial
pressure of oxygen; SVS, Society for Vascular Surgery.
aHistory of transient ischemic attack/stroke, presence of 50% carotid
artery stenosis, or both.
bSee Table I, online only.
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Volume 49, Number 6 Oderich et al 1479.e2Table IV (online only). Angiographic features and
extent of disease in 229 patients with chronic mesenteric
ischemia treated with open (OR) or endovascular (ER)
mesenteric artery revascularizationa
Variable
OR (n  146) ER (n  83)
No. (%) No. (%)
Single-vessel disease 3 (2) 2 (3)
Two-vessel disease 63 (43) 30 (36)
Three-vessel disease 80 (55) 51 (61)
Celiac axis
Normal 10 (7) 5 (6)
Stenosis 40% 5 (3) 5 (6)
Stenosis 40%-69% 6 (4) 4 (5)
Stenosis 70% 87 (60) 59 (71)
Occlusionb 38 (26) 10 (12)
Superior mesenteric artery
Normal 1 (1) 4 (5)
Stenosis 40% 4 (3) 6 (7)
Stenosis 40%-69% 3 (2) 4 (5)
Stenosis 70% 78 (53) 62 (75)
Occlusionb 60 (41) 7 (8)
Inferior mesenteric artery
Normal 16 (11) 7 (8)
Stenosis 40% 13 (9) 10 (12)
Stenosis 40%-69% 9 (6) 0 (0)
Stenosis 70% 57 (39) 28 (34)
Occlusionb 37 (25) 38 (46)
Not evaluated 14 (10) 0 (0)
Abdominal aorta
Normal 74 (52) 41 (49)
Aneurysmal diseaseb 26 (18) 9 (11)
Occlusive diseaseb 43 (30) 33 (40)
ER, endovascular revascularization; OR, open revascularization.
aFor analysis of number of diseased vessels we included only arteries with
stenosis 70% or occlusions. The degree of stenosis was established based
on review of reports of mesenteric angiographies obtained using anteropos-
terior and lateral views or review. Mesenteric runoff data were not system-
atically reviewed.
bP  .05.
Table V (online only). Technical details of endovascular
interventions in 105 mesenteric arteries in 83 patients
with chronic mesenteric ischemia
Detail No. (%) or Mean  SD
Total patients 83
Single-vessel 62 (75)
Two-vessels 20 (24)
Three-vessels 1 (1)
Total arteries 105
Angioplasty and stenting 76 (72)
Celiac axis 29 (27)
Superior mesenteric artery 45 (43)
Inferior mesenteric artery 2 (2)
Stent diameter 6.1  0.8
5 mm 11 (14)
6 mm 31 (41)
7 mm 28 (37)
8-10 mm 6 (8)
Total stented length 17.3  5.1
12-15 mm 29 (38)
15-20 mm 35 (46)
20-30 mm 9 (12)
30-40 mm 3 (4)
Angioplasty only 29 (28)
Celiac axis 9 (9)
Superior mesenteric artery 17 (16)
Inferior mesenteric artery 3 (3)
Balloon diameter 5.9  0.1
5 mm 5 (5)
6 mm 16 (15)
7 mm 8 (8)
SD, Standard deviation.
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June 20091479.e3 Oderich et alFig 4 (online only). A, Kaplan-Meier estimates of primary and
secondary patency rates in patients treated for chronic mesenteric
ischemia treated with percutaneous transluminal angioplasty
(PTA) or stent placement. B, Patency rates are shown for percu-
taneous celiac and superior mesenteric artery (SMA) interventions.
Table IX (online only). Early periprocedural
complications in 229 patients treated for chronic
mesenteric ischemia with either open or endovascular
revascularization.
Complications
OR (n  146),
No. (%)
ER (n  83),
No. (%) P
Any complication 53 (36) 15 (18) .003
Cardiac complications 14 (10) 2 (2) .04
Myocardial infarction 6 (4) 2 (2) NS
Arrhythmia 8 (5) 0 (0) .05
Congestive heart failure 2 (1) 0 (0) NS
Pulmonary complications 22 (15) 1 (1) .0008
Pneumonia 8 (5) 0 (0) .05
Pneumothorax 2 (1) 0 (0) NS
Respiratory failure 8 (5) 1 (1) .05
Prolonged
MV/tracheostomy 6 (4) 0 (0) NS
Renal complications 5 (3) 7 (8) NS
Acute renal failure 5 (3) 7 (8) NS
Dialysis 0 (0) 0 (0) NS
TIA/stroke 0 (0) 0 (0) NS
Gastrointestinal
complications 20 (14) 5 (6) NS
Prolonged ileus 12 (8) 0 (0) .05
Gastrointestinal
bleeding 2 (1) 2 (2)
NS
Pancreatitis 2 (2) 0 (0) NS
Ascites/compartment
syndrome 1 (0.5) 0 (0) NS
Ischemic colitis 1 (0.5) 2 (2) NS
HIT/pulmonary
embolism 3 (2) 0 (0) NS
Surgical complications 9 (6) 7 (8) NS
Mesenteric artery/graft
thrombosis 3 (2) 3 (4) NS
Wound
infection/dehiscence 4 (3) NA ...
Major bleedinga 3 (2) 0 (0) NS
Bowel infarction 1 (0.5) 3 (4) NS
Puncture site
complications NA 4 (4) ...
Pseudoaneurysm NA 2 (2) ...
Distal thrombosis/
embolization NA 2 (2) ...
Early reintervention 7 (5) 5 (6) NS
Wound débridement 2 (1) 0 (0) NS
Exploration for
bleeding 3 (2) 0 (0) NS
Bowel resection 1 (0.5) 3 (4) NS
Mesenteric
thrombectomy/
revision 2 (1) 2 (2) NS
Mesenteric lytic therapy 0 (0) 1 (1) NS
Repair pseudoaneurysm 0 (0) 2 (2) NS
Extremity
thrombectomy 0 (0) 2 (2) NS
ER, endovascular revascularization; HIT, Heparin-induced thrombocyto-
penia; MV, mechanical ventilation; NA, not applicable; NS, not significant;
OR, open revascularization; TIA, transient ischemic attack.
aMajor bleeding requiring exploration.
